Your Nutrition and Immunity Matter in Cancer: What the Prognostic Nutritional Index Tells Us

Table of Contents

• Key Points
• Background: Why Nutrition and Immunity Matter in Cancer
• What Is the Prognostic Nutritional Index (PNI)?
• Study Methods: How This Umbrella Review Was Conducted
• Overall Findings: Low PNI Predicts Poor Outcomes
• Findings in Digestive System Cancers
• Findings in Reproductive System Cancers
• Findings in Urinary System Cancers
• Findings in Lung Cancer
• Findings in Head, Neck, and Brain Cancers
• Findings in Lymphoma
• Clinical Implications: What This Means for Patients
• Study Limitations: What This Review Could Not Prove
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• A low Prognostic Nutritional Index, a blood-based score combining albumin and lymphocyte count, was linked to worse survival across 12 categories of malignant tumors in an umbrella review of 74 meta-analyses.
• The strongest association appeared in cervical cancer, where low PNI was linked to an overall survival hazard ratio of 2.98, based on eight studies with 2,391 patients.
• In patients receiving immunotherapy, low PNI predicted significantly poorer responses, including an overall survival hazard ratio of 2.68 in advanced non-small cell lung cancer.
• Evidence quality was predominantly low or very low: 89.3% of outcomes were graded low or very low, and no outcomes were rated high quality.
• PNI cannot yet be recommended as a standalone prognostic or decision-making tool; it should be discussed with your oncology team alongside other factors.

Background: Why Nutrition and Immunity Matter in Cancer

Malnutrition is an extremely common problem in cancer patients. It creates what researchers describe as a "vicious cycle" involving inflammation and immune exhaustion—a state where the body's immune system becomes worn out and less able to fight the tumor. This cycle impairs treatment tolerance, reduces quality of life, and worsens prognosis.

The cycle is driven by several interconnected processes. Tumors consume large amounts of nutrients, the body secretes pro-inflammatory cytokines (signaling proteins that promote inflammation), and immune function becomes disrupted. These pathways link nutritional status directly to cancer outcomes, and accumulating evidence confirms that nutritional status is an independent prognostic factor—meaning it predicts survival regardless of other factors—for cancer patients.

This is where the Prognostic Nutritional Index enters the picture. First introduced by Onodera and colleagues in 1984, the PNI is a simple, inexpensive biomarker that combines two routine blood measurements to reflect both nutritional reserves and immune status.

What Is the Prognostic Nutritional Index (PNI)?

The PNI is calculated using a straightforward formula:

PNI = serum albumin (g/dL) + 5 × total lymphocyte count (10⁹/L)

In plain terms, this means doctors measure two things from a standard blood draw:

• Serum albumin—a protein made by the liver that reflects your nutritional status. Low albumin suggests malnutrition or chronic illness.
• Total lymphocyte count—a type of white blood cell that is central to immune function. Low lymphocytes can signal immune suppression.

A low PNI score indicates both poor nutrition and weakened immunity. Extensive research has already validated PNI as a prognostic marker in several cancers, including hepatocellular carcinoma (liver cancer), prostate cancer, biliary tract cancers, and gastric cancer—where it also appears to influence how well immunotherapy works.

Study Methods: How This Umbrella Review Was Conducted

This study is called an "umbrella review," which means the researchers didn't study patients directly. Instead, they systematically gathered and analyzed the results of existing systematic reviews and meta-analyses—studies that pool data from multiple clinical trials to reach stronger conclusions. Think of it as a "review of reviews," sitting at the very top of the evidence hierarchy.

Here's how the research was conducted step by step:

1. Literature search: The team searched four major medical databases—PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews—from the inception of each database until April 2025.
2. Screening: Two investigators independently screened titles and abstracts and evaluated full texts. Disagreements were resolved by a third reviewer. They also manually checked reference lists of included studies for additional relevant meta-analyses.
3. Inclusion criteria: Only meta-analyses that pooled statistical results and examined survival outcomes related to PNI in cancer patients were included. Systematic reviews without meta-analyses were excluded.
4. Handling overlap: When multiple meta-analyses covered the same patient population and outcome, the team applied a predefined hierarchy to select only the "best" one: newest publication (if the time gap was ≥2 years), larger sample size (if the time gap was <2 years), and higher AMSTAR quality score (if the first two criteria didn't differentiate).
5. Quality assessment: The AMSTAR tool (A MeaSurement Tool to Assess systematic Reviews) rated each included meta-analysis on 11 items, giving a score from 0 to 11. Scores of 8 or higher were considered high quality, 4–7 moderate, and 3 or lower low quality.
6. Evidence grading: The GRADE framework was used to rate the overall certainty of evidence for each outcome, integrating heterogeneity (I² statistic, which measures how much study results vary) and publication bias (assessed via Egger's regression test).

The full search identified 1,221 unique articles after removing duplicates. After applying inclusion criteria, 74 meta-analyses were selected, containing 159 outcome measures, from which 111 outcome indicators were extracted. The study was prospectively registered with PROSPERO (registration number CRD42025111093).

Overall Findings: Low PNI Predicts Poor Outcomes

The central finding of this umbrella review is clear: a low PNI is significantly associated with poor prognosis across 12 categories of malignant tumors, encompassing the digestive, reproductive, urinary, respiratory, head and neck, lymphoid, and central nervous system cancers, as well as unclassified tumors and elderly cancer patient populations.

Of the 111 outcome indicators extracted, 103 (92.8%) showed statistically significant negative correlations between PNI and prognosis, with hazard ratios (HRs) ranging from 1.15 to 2.98 (p < 0.05). To understand hazard ratios: an HR of 2.0 means that patients with low PNI are approximately twice as likely to experience the outcome (such as death or cancer progression) compared to those with higher PNI, at any given point in time.

However, the quality of this evidence was a concern. Applying the GRADE framework:

• 58 outcomes were rated "very low" quality
• 34 outcomes were rated "low" quality
• 11 outcomes were rated "moderate" quality
• 0 outcomes were rated "high" quality

In other words, 89.3% of outcomes were low or very low quality. This was largely attributed to high heterogeneity (47.8% of outcomes had I² > 50%, meaning study results varied substantially), publication bias (present in 40% of outcomes), and limitations in AMSTAR methodology scores.

Reassuringly, all 11 moderate-quality outcomes showed substantial effect sizes, suggesting that PNI's prognostic value is real even when only the most reliable evidence is considered.

In terms of research distribution: digestive system tumors accounted for the largest share of outcome measures (29%), followed by urinary system (18%), reproductive system (16%), head and neck (14%), respiratory system (11%), other classifications (6%), central nervous system (4%), and lymphoma (2%). In terms of studies rather than outcomes, reproductive system tumors had the highest share (34%), followed by lymphoma (18%).

Findings in Digestive System Cancers

The digestive system category contained the largest number of meta-analyses (n = 25). Here are the specific results across different tumor types:

Pancreatic Cancer and Related Tumors

Low PNI was linked to worse outcomes across three pancreatic cancer contexts. For pancreatic cancer overall, the OS HR was 1.48. For periampullary cancer (tumors near the head of the pancreas) after surgery called pancreaticoduodenectomy, the OS HR was 1.60 and disease-free survival (DFS) HR was 1.44. For pancreatic cancer receiving neoadjuvant (pre-surgical) therapy, the OS HR was 1.66 and recurrence-free survival (RFS) HR was 1.37. Both analyses received a "very low" GRADE quality rating.

Esophageal Cancer

Esophageal carcinoma (EC) had an OS HR of 1.51 with low PNI, while esophageal squamous cell carcinoma (ESCC) had an OS HR of 1.42. Notably, one moderate-quality finding emerged: EC patients with low PNI had significantly poorer cancer-specific survival (CSS HR = 2.18)—meaning they were more than twice as likely to die from their cancer—supported by consistent results across three studies with minimal heterogeneity (I² = 39.0%).

Gastric Cancer

Patients with gastric cancer who had undergone gastrectomy (surgical removal of the stomach) faced adverse outcomes with reduced PNI: OS HR = 1.82 and RFS HR = 2.52. Those with gastric or gastroesophageal junction carcinoma receiving immune checkpoint inhibitors (a form of immunotherapy) also fared worse: OS HR = 1.72 and progression-free survival (PFS) HR = 1.41.

Colorectal, Liver, and Biliary Tract Cancers

Reduced PNI was associated with compromised survival in several cancers:

• Colorectal carcinoma with preoperative tumor resection: OS HR = 1.87
• Hepatocellular carcinoma (liver cancer): preoperative OS HR = 1.82, postoperative OS HR = 1.60, DFS/RFS HR = 1.48
• Biliary tract carcinoma (bile duct and gallbladder cancers): advanced disease OS HR = 2.25, resectable disease OS HR = 1.84, comprehensive OS HR = 1.91, DFS HR = 1.93

Other digestive system findings showed that patients with overall digestive system carcinoma had poorer OS with low PNI (HR = 1.83). For gastrointestinal stromal tumors (GISTs), a rare type of digestive tract tumor, moderate-quality evidence showed that reduced PNI strongly correlated with elevated recurrence risk (RFS HR = 2.02), based on eight studies with no heterogeneity (I² = 0.0%). Gastrointestinal cancers treated with immune checkpoint inhibitors also demonstrated worse PFS (HR = 1.35) and OS (HR = 1.89) when PNI was low.

Findings in Reproductive System Cancers

Thirteen meta-analyses focused on reproductive system tumors. This category contained some of the strongest and highest-quality evidence in the entire review.

Breast Cancer

Moderate-quality evidence confirmed that PNI strongly predicts overall survival in breast cancer patients. In preoperative patients (n = 2,010 pooled participants), the OS HR was 2.56. In postoperative patients (n = 3,769), the OS HR was 2.63. Both subgroups showed no heterogeneity (I² = 0.0%), robust methodological quality (AMSTAR score = 9 out of 11), and no evidence of publication bias (Egger's test p = 0.926 for preoperative, p = 0.525 for postoperative). This means breast cancer patients with low PNI were roughly 2.5 times more likely to die from any cause compared to those with better nutritional status.

Cervical Cancer

Cervical cancer provided the single strongest effect size in the entire review: low PNI was associated with an OS HR of 2.98 (based on eight studies, n = 2,391 patients) and a PFS HR of 2.43 (based on six studies, n = 2,088 patients). Heterogeneity was low (I² = 35.4% for PFS, 6.1% for OS), no publication bias was detected (Egger's test p = 0.573 for PFS, p = 0.819 for OS), and the AMSTAR score was 8, indicating high methodological rigor. This was rated moderate-quality evidence.

Prostate, Ovarian, and Endometrial Cancers

Prostate cancer patients with reduced PNI faced higher risks of diminished progression-free survival (PFS HR = 1.97) and overall survival (OS HR = 1.99). For ovarian cancer, low PNI was significantly associated with poorer PFS (HR = 1.351) and OS (HR = 1.493). Endometrial cancer patients demonstrated poorer OS (HR = 2.01) and PFS/DFS/RFS (HR = 2.49) with low PNI.

Across all gynecological cancers combined, low PNI correlated with poorer OS (HR = 1.60), PFS (HR = 1.63), and DFS (HR = 1.73).

Findings in Urinary System Cancers

Ten meta-analyses addressed urinary system tumors, including kidney, bladder, and urothelial cancers.

For renal cell carcinoma (kidney cancer), patients who underwent nephrectomy (kidney removal) demonstrated worse survival with low PNI: OS HR = 1.57 and RFS HR = 1.69. Those receiving targeted therapy had an OS HR of 1.78. Moderate-quality evidence emerged specifically for renal cell carcinoma patients receiving targeted therapy: low PNI was linked to shorter PFS (HR = 2.03), based on two consistent studies (n = 303 patients). In broader renal cell carcinoma analyses, low PNI was associated with OS HR = 1.67, PFS HR = 1.72, RFS HR = 2.14, cancer-specific survival (CSS) HR = 1.17, and DFS HR = 1.15.

For upper tract urothelial carcinoma (cancers of the kidney pelvis or ureter), low PNI predicted poorer OS (HR = 1.92), CSS/disease-specific survival (HR = 1.79), and DFS/PFS/RFS (HR = 1.57). Urothelial carcinoma patients more broadly showed similar trends with OS (HR = 1.68) and DFS/PFS/RFS (HR = 1.75).

Bladder cancer patients with low PNI experienced decreased OS (HR = 1.80) and RFS (HR = 1.53). Uveal melanoma (a rare eye cancer classified under urinary malignancies in this review's data grouping) patients with low PNI had poorer OS (HR = 1.72).

Findings in Lung Cancer

Lung cancer findings were particularly notable because of their relevance to immunotherapy, a rapidly growing treatment approach.

Small Cell and Non-Small Cell Lung Cancer

Small cell lung cancer (SCLC) patients with low PNI faced poorer OS (HR = 1.43). Non-small cell lung cancer (NSCLC) patients demonstrated compromised OS (HR = 1.59), PFS (HR = 1.52), and DFS/RFS (HR = 1.74) with low PNI.

Immunotherapy (Immune Checkpoint Inhibitor) Findings

The strongest lung cancer effects appeared in patients receiving immune checkpoint inhibitor therapy—drugs that help the immune system recognize and attack cancer cells. Among these patients, low PNI significantly predicted worse outcomes:

• Advanced NSCLC with ICI: OS HR = 2.68, PFS HR = 1.84
• Advanced lung cancer with ICI: OS HR = 2.56, PFS HR = 1.29
• Broader lung cancer ICI cohort: OS HR = 2.33, PFS HR = 1.96
• Before starting immunotherapy: patients with low PNI had a 150% increased risk of death (OS HR = 2.50) and a 94% increased risk of cancer progression (PFS HR = 1.94)

In lung cancer patients receiving chemotherapy rather than immunotherapy, low PNI was linked to poorer PFS (HR = 1.32). Across all lung cancer patients combined, low PNI was associated with poorer OS (HR = 1.72).

Findings in Head, Neck, and Brain Cancers

Head and neck cancer (HNC) patients with low PNI had poorer OS (HR = 1.93), distant metastasis-free survival or DMFS (HR = 2.04), and disease-specific survival (DSS HR = 2.20). Those undergoing radiotherapy demonstrated poorer DMFS (HR = 1.96) and OS (HR = 1.97) with low PNI.

Nasopharyngeal carcinoma patients with low PNI showed poorer OS (HR = 1.89) and PFS (HR = 1.59). Moderate-quality evidence highlighted that low PNI correlated with worse DMFS (HR = 2.01).

For central nervous system malignancies, glioma patients with low PNI had elevated PFS (HR = 1.41) and OS (HR = 1.64) risk. Glioblastoma (GBM) patients—those with the most aggressive type of brain tumor—showed increased PFS (HR = 1.59) and OS (HR = 1.85) risk with low PNI. All brain cancer analyses were graded as very low certainty evidence, and publication bias could not be assessed due to insufficient studies.

Findings in Lymphoma

Only two meta-analyses examined PNI's prognostic value in lymphoma, despite lymphoma accounting for a substantial 18% of included studies. Overall, lymphoma patients with low PNI faced significantly elevated OS (HR = 2.17) and PFS (HR = 1.79) risk.

Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, provided moderate-quality evidence: low PNI predicted increased OS risk (HR = 2.14, representing a 114% increase in death risk), based on seven studies (n = 1,311 patients) with moderate heterogeneity (I² = 41.1%) and no publication bias (Egger's test p = 0.391).

Clinical Implications: What This Means for Patients

These findings carry several important messages for cancer patients and their care teams.

First, nutrition is not a "soft" issue in cancer care—it's a survival issue. The consistent association between low PNI and worse outcomes across virtually every cancer type studied reinforces that malnutrition and immune dysfunction are not merely unpleasant side effects of cancer but are biologically linked to how the disease progresses and how well treatment works.

Second, PNI may be particularly valuable in predicting immunotherapy responses. The elevated hazard ratios seen in patients receiving immune checkpoint inhibitors—including an OS HR of 2.68 for advanced NSCLC, 2.56 for advanced lung cancer, and 2.02 for gastrointestinal stromal tumors—suggest that a patient's nutritional-immune status shapes whether their immune system can mount an effective anti-tumor response. This makes biological sense: immunotherapy relies on a functional immune system, and low lymphocyte counts directly reflect immune compromise.

Third, PNI is eminently practical. It requires only a standard complete blood count with differential and a serum albumin level—tests that are already routinely performed in cancer patients. It costs nothing extra, requires no special equipment, and can be calculated by any clinician in seconds.

However, the authors are careful to emphasize: because the quality of most available evidence was low or very low, PNI cannot yet be recommended as a standalone prognostic or decision-making tool across all tumor types. It should not, on its own, determine whether a patient receives a particular treatment or how aggressively they are treated.

Study Limitations: What This Review Could Not Prove

This umbrella review has several important limitations that patients should understand:

• Low evidence quality: 89.3% of outcomes were graded as low or very low quality. This means the true effects of PNI could differ from what the included studies reported.
• High heterogeneity: Nearly half of the outcomes (47.8%) had I² values exceeding 50%, indicating substantial variability among studies. This may reflect differences in cancer stages, treatment protocols, PNI cutoff values, and patient populations.
• Publication bias: Evidence of publication bias was detected in 40% of outcomes, meaning studies with negative results may have gone unpublished, potentially inflating the apparent strength of PNI's prognostic value.
• No high-quality evidence: Zero outcomes were rated as "high" quality using the GRADE framework, limiting definitive conclusions.
• Potential patient overlap: Different subgroup analyses within the same meta-analysis may have included overlapping patient cohorts, which could not be adjusted for in this review.
• Insufficient data in some cancers: Only two meta-analyses addressed lymphoma, and central nervous system malignancy analyses lacked sufficient studies to assess publication bias.
• Variable PNI cutoff values: Because this review extracted pooled results from original meta-analyses, the specific PNI cutoff values used to define "low" PNI may have varied across studies, and the review did not standardize these thresholds.

Recommendations for Patients

Based on this research, here are practical steps patients and caregivers can consider:

1. Discuss your PNI with your oncology team. Ask about your serum albumin and lymphocyte counts. If your PNI is low, ask whether nutritional support—such as working with a registered dietitian, using oral nutritional supplements, or other interventions—might be appropriate.
2. Treat nutrition as part of your cancer treatment. This review reinforces that nutritional status is linked to survival across many cancer types. Eating enough protein, maintaining weight, and addressing any swallowing or digestive difficulties early can make a meaningful difference.
3. Don't interpret a low PNI as a "death sentence." The hazard ratios in this review describe group-level statistics, not individual outcomes. Many patients with low PNI still respond well to treatment. PNI is one piece of information, not a verdict.
4. Look for nutritional assessments at cancer centers. Many major cancer centers now conduct routine malnutrition screening. If your center doesn't, ask for a referral to nutritional services.
5. Be aware of PNI's role in immunotherapy discussions. If you're receiving or considering immune checkpoint inhibitors, your doctor may use PNI along with other factors to assess your overall fitness for treatment. A low PNI might prompt supportive measures rather than denial of treatment.
6. Participate in research if possible. The authors call for rigorously designed, multi-center studies to validate PNI's clinical utility. Patients participating in clinical trials that track nutritional markers are helping build better evidence.

The bottom line: the Prognostic Nutritional Index is a simple, inexpensive, and broadly informative marker that links nutrition and immunity to cancer outcomes. While the current evidence base has significant quality limitations, the consistent pattern across diverse cancers, and particularly its strong association with immunotherapy outcomes, makes PNI a promising tool worth discussing with your healthcare team.

Frequently Asked Questions

What is the Prognostic Nutritional Index (PNI)?

The PNI is a simple blood-based score that reflects both nutrition and immune health. It is calculated from two routine measurements: serum albumin, a liver protein showing nutritional status, and total lymphocyte count, a white blood cell type central to immunity. A low PNI indicates both poor nutrition and weakened immunity. It was first introduced in 1984 and costs nothing extra to calculate.

How is the PNI calculated?

The formula is PNI = serum albumin (g/dL) plus 5 times total lymphocyte count (10⁹/L). In plain terms, doctors measure two things from a standard blood draw: serum albumin, which reflects your nutritional status, and total lymphocyte count, which reflects immune function. A low score means both poor nutrition and weakened immunity. Any clinician can calculate it in seconds from routine tests.

What did this review find about low PNI and cancer survival?

An umbrella review of 74 meta-analyses found that low PNI was significantly associated with poor prognosis across 12 categories of malignant tumors. Of 111 outcome indicators, 103 showed statistically significant negative correlations, with hazard ratios ranging from 1.15 to 2.98. However, 89.3% of outcomes were rated low or very low quality, so PNI should be interpreted with caution.

Does low PNI affect immunotherapy outcomes?

The review found that low PNI predicted significantly poorer responses in patients receiving immunotherapy. In advanced non-small cell lung cancer patients on immune checkpoint inhibitors, the overall survival hazard ratio was 2.68. Before starting immunotherapy, patients with low PNI had a 150% increased risk of death. This makes biological sense because immunotherapy relies on a functional immune system, and low lymphocyte counts reflect immune compromise.

Can PNI be used to decide my treatment?

Not on its own. Because most available evidence was low or very low quality, PNI cannot yet be recommended as a standalone prognostic or decision-making tool across all tumor types. It should not, by itself, determine whether you receive a particular treatment or how aggressively you are treated. Discuss your PNI with your oncology team as one piece of information among many.

What are the limitations of the evidence on PNI?

The review found that 89.3% of outcomes were graded low or very low quality, and zero outcomes were rated high quality. Nearly half of outcomes had high heterogeneity, meaning study results varied substantially. Publication bias was detected in 40% of outcomes. PNI cutoff values also varied across studies, and some analyses may have included overlapping patient groups.

What should I do if my PNI is low?

Discuss your PNI with your oncology team. Ask about your serum albumin and lymphocyte counts. If your PNI is low, ask whether nutritional support, such as working with a registered dietitian or using oral nutritional supplements, might be appropriate. Treat nutrition as part of your cancer treatment. A low PNI is not a death sentence; many patients with low PNI still respond well to treatment.

If my cancer team says my low Prognostic Nutritional Index means I should not get immunotherapy, should I get a second opinion?

A low PNI predicts poorer survival and weaker immunotherapy responses across many cancers, including lung, gastric, and gastrointestinal tumors, but it cannot yet be recommended as a standalone decision-making tool. Most supporting evidence is low or very low quality, and PNI should not by itself determine whether you receive a particular treatment or how aggressively you are treated. A low PNI might reasonably prompt nutritional support rather than denial of therapy. A second opinion can help weigh PNI alongside your full clinical picture. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article Title: Prognostic value of Prognostic Nutritional Index in cancer: an umbrella review of systematic review and meta-analysis.

Journal: Frontiers in nutrition

DOI: 10.3389/fnut.2025.1706534

License: CC BY (open access)

Authors: Yang J, Wang C, Xue J, Ma X, Hou Y, Yuan H, Xia K, Piao L, Zhou X.

Publication Details: Frontiers in Nutrition, Volume 12, Article 1706534. Published 21 January 2026. DOI: 10.3389/fnut.2025.1706534

Registration: PROSPERO registration number CRD42025111093

This patient-friendly article is based on peer-reviewed research published in an open-access journal under the Creative Commons Attribution License (CC BY). It was independently written to translate the original scientific findings for a general audience. This content is for educational purposes only and does not constitute medical advice. Always consult your oncology team about your individual treatment plan.